HIV-1 reverse transcriptase inhibitors have long been central to antiretroviral therapy, effectively impeding the enzyme responsible for converting viral RNA into DNA – a pivotal step in HIV ...

The mechanism of action of NNRTIs is illustrated in Figure 1. Reverse transcriptase catalyzes RNA-dependent and DNA-dependent polymerase activities, which are essential for viral DNA synthesis when ...

Clin Drug Invest. 2007;27(8):509-531. Because of its poor tolerability, regimen complexity and drug-interaction potential relative to other new NRTIs, use of didanosine has decreased over the last few ...

Retrotransposons could have a main role in the development of drug resistance in response to cancer treatment, according to a new study out of the Roswell Park Comprehensive Cancer Center. The ...

The Aicardi–Goutières syndrome is a genetic encephalopathy that is associated with childhood illness and death. The syndrome is hypothesized to be due to misidentification of self-derived nucleic ...

In July 2000, a 58-year-old man infected with the human immunodeficiency virus (HIV) began treatment with highly active antiretroviral therapy, which initially consisted of zidovudine, lamivudine, and ...

About RDEA806 RDEA806 is a novel non-nucleoside reverse transcriptase inhibitor (NNRTI) for the potential treatment of HIV infection. Based on preclinical and clinical studies to-date, Ardea believes ...

REDWOOD CITY, Calif., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced the launch of its ...

After 48 weeks of treatment, TPN-101 reduced the levels of neurofilament light chain and interleukin 6, both key biomarkers of neurodegeneration and neuroinflammation in PSP. The Food and Drug ...

The inhibition of HIV-1’s replicative machinery remains a cornerstone in the battle against AIDS. Central to this approach are inhibitors targeting reverse transcriptase (RT) and integrase. Reverse ...